SAGE
Sage Therapeutics
SAGE
SAGE
Delisted
SAGE was delisted on the 30th of July, 2025.
174 hedge funds and large institutions have $2.46B invested in Sage Therapeutics in 2017 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 74 increasing their positions, 52 reducing their positions, and 37 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
35% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 37
39% less call options, than puts
Call options by funds: $66.5M | Put options by funds: $109M
Holders
174
Holding in Top 10
3
Calls
$66.5M
Puts
$109M
Top Buyers
| 1 | +$70.3M | |
| 2 | +$45.1M | |
| 3 | +$12.3M | |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$11.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.5M |
Top Sellers
| 1 | -$17.7M | |
| 2 | -$17.6M | |
| 3 | -$15.3M | |
| 4 |
Jennison Associates
New York
|
-$13.4M |
| 5 |
Barclays
London,
United Kingdom
|
-$9.25M |